All Trials

A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative and Gastrin Releasing Peptide Receptor Positive Advanced Breast Cancer Experiencing Early Relapse From (Neo)Adjuvant Endocrine Therapy or Who Have Progressed on Endocrine Therapy in Combination With a CDK4/6 Inhibitor for Advanced Disease

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with ER-positive, HER2-negative, GRPR-positive advanced breast cancer who have relapsed early after (neo)adjuvant endocrine therapy or progressed on prior endocrine therapy plus a CDK4/6 inhibitor, with up to one prior line of advanced therapy and no prior fulvestrant. Patients receive [177Lu]Lu-NeoB, a GRPR-targeted radioligand delivering beta radiation, in combination with ribociclib and fulvestrant.

ClinicalTrials.gov ID: NCT05870579

Phase 1 Study of X-PACT (X-ray Psoralen Activated Cancer Therapy) for Intra-tumoral Injection of Superficial Tumors in Patients With Advanced Head and Neck Cancer, Breast Cancer, Soft Tissue Sarcoma or Melanoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with advanced, superficial, and injectable head and neck cancer, breast cancer, soft tissue sarcoma, or melanoma that has progressed on or is ineligible for standard therapy. Patients receive intra-tumoral X-PACT, a novel approach using methoxsalen and a phosphor device activated by local X-ray to induce tumor cell death.

ClinicalTrials.gov ID: NCT04389281

A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-2485 in Adult Patients With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This study enrolls adults with advanced or metastatic solid tumors (including ER+ breast cancer, triple negative breast cancer, ARID1A-mutated tumors, and small cell lung cancer) who have progressed on or cannot tolerate standard therapies, testing oral JAB-2485, a highly selective Aurora kinase A (AURKA) inhibitor. All patients must have ECOG 0-1 and measurable disease.

ClinicalTrials.gov ID: NCT05490472

Phase 1b/2 Study to Evaluate Antibody-Drug Conjugate Sacituzumab Govitecan in Combination With PARP Inhibitor Talazoparib in Patients With Metastatic Breast Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with metastatic triple-negative breast cancer (ER-, PR-, HER2-) and tests the combination of sacituzumab govitecan (an anti–Trop-2 antibody-drug conjugate delivering SN-38) with talazoparib (a PARP inhibitor), assessing safety and preliminary efficacy in this population.

ClinicalTrials.gov ID: NCT04039230

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with advanced, unresectable, or metastatic solid tumors (excluding primary CNS tumors) who have progressed on or are intolerant to standard therapies, with preferential inclusion of BRCA2 loss-of-function cases. Patients receive ETX-19477, a novel reversible small molecule inhibitor of poly(ADP-ribose) glycohydrolase (PARG), given as monotherapy.

ClinicalTrials.gov ID: NCT06395519

A Phase 1 Open-Label, First-in-Human Trial of Oral MBQ-167 as Single Agent in Participants With Advanced Breast Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with advanced breast cancer whose disease has progressed after all standard therapies, treating them with oral MBQ-167, a novel dual inhibitor of the Rho GTPases Rac and Cdc42. Patients must be able to swallow oral medication, have adequate organ function, and may have stable, asymptomatic brain metastases.

ClinicalTrials.gov ID: NCT06075810

A Phase 1, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Cyclin A/B-RxL Inhibitor CID-078 in Patients With Advanced Solid Tumor Malignancies

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults and adolescents (≥12 years, ≥40 kg) with advanced or metastatic solid tumors refractory to standard therapy—including dedicated cohorts for TNBC, SCLC, and tumors with RB1 alteration—for treatment with CID-078, a first-in-class oral macrocyclic inhibitor that blocks cyclin A/B-RxL interactions to induce cell cycle arrest. All patients receive CID-078 monotherapy in 21-day cycles.

ClinicalTrials.gov ID: NCT06577987

SHARON: Study of Metastatic Cancers in Patients With a Defect in a Homologous Recombination Gene Using Autologous Stems Cells and Potentiated Redox Cycling to Overcome Drug Resistance to Nitrogen Mustard Derivatives

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with metastatic pancreatic (ductal or acinar) or HER2-negative breast cancer harboring BRCA1, BRCA2, or PALB2 mutations, and treats them with high-dose melphalan and BCNU in combination with vitamin B12b, escalating doses of vitamin C, and low-dose ethanol, followed by autologous hematopoietic stem cell rescue. The investigational regimen aims to overcome drug resistance in homologous recombination-deficient tumors by exploiting oxidative stress pathways.

ClinicalTrials.gov ID: NCT04150042

A Phase 1 Study of MOMA-313 Given as Monotherapy or in Combination With a PARP Inhibitor in Participants With Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors harboring homologous recombination deficiency (HRD), investigating the safety and activity of the investigational oral polymerase theta (Polθ) helicase inhibitor MOMA-313 as monotherapy or in combination with the PARP inhibitor olaparib. Eligible combination therapy patients include those with metastatic prostate, breast, or pancreatic cancer and must be PARP inhibitor naive.

ClinicalTrials.gov ID: NCT06545942

A Multicenter FIH Dose Escalation and Optimization Phase I/IIa Trial to Investigate Safety, Tolerability, PK, and Efficacy of the 5T4 ADC TUB-030 in Patients With Advanced Solid Tumors (5-STAR 1-01)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with advanced, measurable solid tumors (including NSCLC and head and neck squamous cell carcinoma), evaluating intravenous TUB-030, an antibody-drug conjugate targeting the 5T4 oncofetal antigen and delivering a topoisomerase I inhibitor, in patients with ECOG 0-1 and adequate organ function. Patients may have clinically stable brain metastases and must have completed prior therapies.

ClinicalTrials.gov ID: NCT06657222